News
Public · Published
Wedbush maintains Ultragenyx Pharmaceutical at Neutral, lowers price target to $22 from $25
Wedbush kept its Neutral rating on Ultragenyx Pharmaceutical and cut its price target to $22 from $25, a 12.0% decrease. The revised target implies 32.3% upside from the November 3 closing price of $16.63.
Published:
Updated:
What happened
Wedbush kept its Neutral rating on Ultragenyx Pharmaceutical and cut its price target to $22 from $25, a 12.0% decrease. The revised target implies 32.3% upside from the November 3 closing price of $16.63.
Confirmed
Global impact / market context
The lower target signals Wedbush sees less value than before, while retaining its Neutral view. A price target is an analyst’s estimate, not a promised share price; investors may weigh the change when judging expected gains against the company’s risks.
Analyst inference
The article reports one broker’s view, not a change in Ultragenyx’s reported business results or a company announcement. Its stated 32.3% upside is measured against the November 3 close, so it describes the target’s comparison with that past price, not a forecasted return.
Analyst inference
What to watch
- Check whether Wedbush publishes further changes to its Neutral rating or $22 target; the article does not say whether additional revisions are planned. Analyst inference
- Compare any later analyst targets with the November 3 closing price of $16.63, since the reported 32.3% implied upside uses that specific reference point. Analyst inference
- Look for company updates on results or business plans; this article gives no operating data explaining why Wedbush lowered its target. Analyst inference
Evidence
- Original source link unavailable